Durvalumab Medicine 03 December 2024 Extended indication monotherapy in endometrial cancer that is mismatch repair deficient (dMMR) Therapeutic value No estimate possible yet Total cost Registration phase Registered Product Active substance Durvalumab Domain Oncology Reason of inclusion Indication extension IND Main indication Oncology other Extended indication monotherapy in endometrial cancer that is mismatch repair deficient (dMMR) Current proprietary name Already available biosimilars / generics Proprietary name Imfinzi Manufacturer AstraZeneca Portfolio holder AstraZeneca Mechanism of action PD-1 / PD-L1 inhibitor Route of administration Intracavernous Therapeutical formulation Intravenous drip Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks https://www.ema.europa.eu/en/medicines/human/variation/imfinzi-0 DUO-E studie Durvalumab in combinatie met olaparib heeft CHMP opinie voor de pMMR groep Registration Registration route Decentralised Type of trajectory Normal trajectory Particularity Unknown ATMP No Submission date November 2023 Expected Registration September 2024 Orphan drug No Registration phase Registered Reimbursement Medicine sluice Additional remarks CHMP opinie juli 2024 Therapeutic value Current treatment options Therapeutic value No estimate possible yet This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration Dosage per administration References Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Additional remarks Expected cost per patient per year Cost References Additional remarks Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Unknown Indication extensions References Additional remarks Other information Additional remarks